Simulations Plus Q4 2020 Earnings Report
Key Takeaways
Simulations Plus reported an 18.9% increase in fourth quarter revenue, reaching $9.5 million. The company's diluted EPS for the quarter was $0.11.
Simulations Plus achieved its goal of accelerating organic growth to 15-20%.
Growth was driven by continued strong performance from both software and consulting revenue streams.
A strategic offering was completed, raising net proceeds of approximately $107.7 million to pursue additional acquisitions.
The company continues to generate solid profitability and free cash flow.
Simulations Plus
Simulations Plus
Forward Guidance
Simulations Plus achieved its goal of accelerating organic growth to 15-20%, overcoming headwinds from the COVID-19 pandemic due to continued strong growth from both our software and consulting revenue streams. Our future growth prospects were bolstered by a significant acquisition to expand our software business, growing our European presence, and the recent introductions of new software versions as well as the launch of several important collaborations. We continue to invest in R&D, funded both internally and from leading pharmaceutical and regulatory agencies, building on our leadership position in modelling and simulation for the drug development marketplace.